A Novel Precision Approach to Overcome the “Addiction Pandemic” by Incorporating Genetic Addiction Risk Severity (GARS) and Dopamine Homeostasis Restoration

This article describes a unique therapeutic precision intervention, formulation of enkephalinase inhibitors, enkephalin, and dopamine-releasing neuronutrients, to induce dopamine homeostasis for detoxification treatment individuals genetically predisposed developing reward deficiency syndrome (RDS). The formulations are based on the results addiction risk severity (GARS) test. Based both neurogenetic epigenetic evidence, test evaluates presence genes alleles. Existing evidence demonstrates that novel genetic testing system can successfully stratify potential opioid use disorder (OUD) related risks or before initiating analgesic therapy RDS people in recovery. In case disorders, long-term maintenance agonist treatments like methadone buprenorphine may create RDS, have been existence, but not recognized. will also assess benefit from medication-assisted with augmentation. methodology holds strong promise reducing burden addictive disorders individuals, their families, society as whole by guiding restoration homeostasisthrough anti-reward allostatic neuroadaptations. WC 175.